scholarly journals Recent changes in the American Joint Commission Cancer staging of human papilloma virus related oropharyngeal cancer: validating the present and envisioning the future

2019 ◽  
Vol 8 (S1) ◽  
pp. S6-S6
Author(s):  
Brett A. Miles
Keyword(s):  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Cancer Staging ◽  
Joint Commission ◽  
Papilloma Virus ◽  
The Future

Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms

2015 ◽  
Vol 86 (6) ◽  
pp. 442-447 ◽  
Author(s):  
Lisa Buckley ◽  
Ruta Gupta ◽  
Bruce Ashford ◽  
Joe Jabbour ◽  
Jonathan R. Clark
Keyword(s):  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Papilloma Virus ◽  
Management Paradigms

Long-term survival outcomes in patients with surgically treated oropharyngeal cancer and defined human papilloma virus status

2016 ◽  
Vol 130 (11) ◽  
pp. 1048-1053 ◽  
Author(s):  
O T Dale ◽  
S Sood ◽  
K A Shah ◽  
C Han ◽  
D Rapozo ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Survival Outcomes ◽  
Tumour Stage ◽  
Term Survival ◽  
Papilloma Virus ◽  
Long Term Survival ◽  
Primary Surgery ◽  
Human Papilloma Virus Status

AbstractObjective:This study investigated long-term survival outcomes in surgically treated oropharyngeal cancer patients with known human papilloma virus status.Methods:A case note review was performed of all patients undergoing primary surgery for oropharyngeal cancer in a single centre over a 10-year period. Human papilloma virus status was determined via dual modality testing. Associations between clinicopathological variables and survival were identified using a log-rank test.Results:Of the 107 cases in the study, 40 per cent (n = 41) were human papilloma virus positive. The positive and negative predictive values of p16 immunohistochemistry for human papilloma virus status were 57 per cent and 100 per cent, respectively. At a mean follow up of 59.5 months, 5-year overall and disease-specific survival estimates were 78 per cent and 69 per cent, respectively. Human papilloma virus status (p = 0.014), smoking status (p = 0.021) and tumour stage (p = 0.03) were significant prognostic indicators.Conclusion:The long-term survival rates in surgically treated oropharyngeal cancer patients were comparable to other studies. Variables including human papilloma virus status and tumour stage were associated with survival in patients treated with primary surgery; however, nodal stage and presence of extracapsular spread were non-prognostic.

PO-121: Human Papilloma Virus Infection in Oral and Oropharyngeal Cancer; are They the Same?

2013 ◽  
Vol 106 ◽  
pp. S51-S52
Author(s):  
W. Pongsapich ◽  
S. Siritantikorn ◽  
P. Jotikaprasardhna ◽  
A. Pumchan ◽  
C. Chongkolwatana
Keyword(s):  
Virus Infection ◽  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Human Papilloma Virus Infection ◽  
Papilloma Virus ◽  
Oral And Oropharyngeal Cancer

scholarly journals Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Ken Akashi ◽  
Toshihiko Sakai ◽  
Osamu Fukuoka ◽  
Yuki Saito ◽  
Masafumi Yoshida ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Oropharyngeal Cancer ◽  
Cancer Recurrence ◽  
Circulating Tumor Dna ◽  
Therapeutic Effects ◽  
Multiple Time ◽  
Papilloma Virus ◽  
Cancer Early Detection ◽  
Multiple Time Points ◽  
Tumor Dna

AbstractIn head and neck cancer, early detection of recurrence after treatment is important. The contemporary development of therapeutic agents have improved the prognosis after recurrence; however, no biomarker has been established for evaluating therapeutic effects or detecting recurrence. Recently, circulating tumor DNA (ctDNA), which comprises DNA derived from tumor cells and exists in the form of cell-free DNA in the blood, has attracted attention as a minimally invasive and repeatable biomarker for detecting cancer. We validated the usefulness of ctDNA of human papilloma virus (HPV)-derived sequences as a biomarker in HPV-related p16-positive oropharyngeal cancer by assessing 25 patients with p16-positive oropharyngeal cancer. Blood samples were collected from each patient at multiple time points during the treatment, and the plasma was preserved. The ctDNA was extracted from the plasma and analyzed using digital polymerase chain reaction. HPV-derived ctDNA was detected in 14 (56%) of the 25 patients. In all the patients, the samples were found to be ctDNA-negative after initial treatment. Cancer recurrence was observed in 2 of the 14 patients; HPV-derived ctDNA was detected at the time of recurrence. Our results indicate that HPV-derived ctDNA can be a prospective biomarker for predicting the recurrence of p16-positive oropharyngeal cancer.

Sign in / Sign up

Export Citation Format

Share Document